Worldwide sales for Abbott‘s (NYSE:ABT) diabetes business jumped 33% in the fourth quarter of 2017, the company reported, driven largely by its FreeStyle Libre continuous glucose monitoring system.
The device is the only CGM system on the market that is calibrated at the factory and eliminates the need for people with diabetes to perform routine fingersticks.
Get the full story at our sister site, Drug Delivery Business News.
The post Global sales for Abbott’s diabetes biz jumps 33% in Q4 appeared first on MassDevice.
from MassDevice http://ift.tt/2F8Feak
Cap comentari:
Publica un comentari a l'entrada